Online citations, reference lists, and bibliographies.
← Back to Search

Assessment Of Tumor Response In Malignant Pleural Mesothelioma.

G. Ceresoli, A. Chiti, P. Zucali, F. Cappuzzo, F. De Vincenzo, R. Cavina, M. Rodari, Dario Poretti, F. Lutman, A. Santoro
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Most patients with malignant pleural mesothelioma (MPM) are candidates for chemotherapy during the course of their disease. Assessment of the response with conventional criteria based on computed tomography (CT) measurements is challenging, due to the circumferential and axial pattern of growth of MPM. Such difficulties hinder an accurate evaluation of clinical study results and make the clinical management of patients critical. Several radiological response systems have been proposed, but neither WHO criteria nor the more recent RECIST unidimensional criteria nor hybrid uni- and bidimensional criteria seem to apply to tumor measurement in this disease. Recently, modified RECIST criteria for MPM have been published. Although they are already being used in current clinical trials, they have been criticized based on the high grade of inter-observer variability and on theoretical studies of mesothelioma growth according to non-spherical models. Computer-assisted techniques for CT measurement are being developed. The use of FDG-PET for prediction of response and, more importantly, of survival outcomes of MPM patients is promising and warrants validation in large prospective series. New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment.
This paper references
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
Pemetrexed in malignant pleural mesothelioma.
M. Hazarika (2005)
10.2214/AJR.05.0076
Variability in mesothelioma tumor response classification.
S. Armato (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1148/RADIOL.2252011604
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
S. Prasad (2002)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1016/J.LUNGCAN.2003.07.005
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)
10.1016/J.LUNGCAN.2005.05.024
Phase II trials in mesothelioma: an increasing challenge.
A. Nowak (2005)
10.1056/NEJMRA050276
Positron-emission tomography and assessment of cancer therapy.
M. Juweid (2006)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1007/s00259-006-0133-3
Monitoring chemotherapy and radiotherapy of solid tumors
W. Weber (2006)
10.1016/S0169-5002(05)80890-6
P-397 Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage
D. Fennell (2005)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1118/1.1688211
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
S. Armato (2004)
10.1002/1097-0142(19870615)59:12<2104::AID-CNCR2820591224>3.0.CO;2-I
Serum hyaluronate in malignant pleural mesothelioma
T. Frebourg (1987)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1200/JCO.2001.19.12.3058
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
W. Weber (2001)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1378/CHEST.129.6.1570
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
F. Giesel (2006)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1200/JCO.2004.09.147
Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
A. Nowak (2004)
10.1016/J.EJCA.2006.07.011
Biology and management of malignant pleural mesothelioma.
P. Zucali (2006)
10.1200/JCO.2005.23.16_SUPPL.7177
Monitoring of chemotherapy response in multiple disseminated malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography
T. Kimura (2005)
10.1016/S0169-5002(05)80917-1
P-424 Prediction of response to chemotherapy in malignant pleuralmesothelioma (MPM): Early positron emission tomography (PET) vs. computed tomography (CT)
D. Power (2005)
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
N. Fedarko (2001)
10.1093/CARCIN/21.5.1023
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats.
H. Sandhu (2000)
10.1097/00005382-200605000-00006
Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
M. Truong (2006)
10.1677/ERC.1.00775
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
A. Martinetti (2004)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1016/S0009-9260(99)90824-3
Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases.
C. Ng (1999)
10.1200/jco.2005.23.16_suppl.7066
Decreased PET SUV after induction chemotherapy is associated with improved survival in malignant pleural mesothelioma (MPM)
R. Flores (2005)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1016/S0197-2456(00)00058-1
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
R. Mick (2000)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1200/JCO.2006.06.6068
Positron emission tomography as an imaging biomarker.
W. Weber (2006)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1002/cncr.20315
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma
P. Hollen (2004)
10.1378/CHEST.118.3.604
MRI and CT in the differential diagnosis of pleural disease.
J. Hierholzer (2000)
10.1007/s00259-004-1633-7
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
G. Goerres (2004)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1200/JCO.2005.05.1359
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
J. Francart (2006)
10.1200/JCO.2003.12.004
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
W. Weber (2003)
10.1093/ANNONC/MDF256
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
K. Spaepen (2002)
Use of PET for monitoring cancer therapy and for predicting outcome.
W. Weber (2005)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/S0169-5002(05)80207-7
O-074 Comparison of FDG-PET and CT scans to assess response to chemotherapy in patients with malignant pleural mesothelioma
M. Byrne (2005)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/J.LUNGCAN.2005.03.030
CT, RECIST, and malignant pleural mesothelioma.
A. Nowak (2005)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1200/JCO.2006.06.8080
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
N. Hylton (2006)
10.1200/JCO.2006.06.6159
New technologies and directed agents for applications of cancer imaging.
M. Atri (2006)
10.1097/01.rli.0000208222.03256.ba
Monitoring of Lung Motion in Patients With Malignant Pleural Mesothelioma Using Two-Dimensional and Three-Dimensional Dynamic Magnetic Resonance Imaging: Comparison With Spirometry
C. Plathow (2006)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.1007/s00520-005-0837-0
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso
P. Hollen (2005)



This paper is referenced by
10.1016/J.PNEUMO.2010.07.010
Quelle place en oncologie thoracique pour la tomographie par émission de positons au 18FDG (TEP-FDG) en 2010 ?
F. Vaylet (2010)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1016/j.ejrad.2016.11.009
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Shingo Kanemura (2017)
10.3779/j.issn.1009-3419.2010.01.10
Analysis of the Effect of Radiotherapy on Malignant Pleural Mesothelioma when Given on Adjuvant or Palliative Basis
Hesham A El Hossieny (2010)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1097/JTO.0b013e318208c83d
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
10.4081/MONALDI.2009.374
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
B. Grigoriu (2009)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1016/J.IJROBP.2010.10.050
In Response to Dr. Russi and Colleagues
M. Scorsetti (2011)
DiagnostiC stRategies aimeD to monitoR CanCeR Patients tReateD with new moleCulaR
J. Camilo (2012)
10.1093/ejcts/ezs624
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.
G. Marulli (2013)
10.1007/s00259-010-1704-x
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival
V. Gerbaudo (2010)
10.1002/cam4.1182
Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
P. Zucali (2017)
10.3233/DMA-2011-0866
Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
A. Franko (2012)
10.1016/J.PNEUMO.2008.12.002
Association pemetrexed–cisplatine en première ligne dans le mésothéliome pleural malin non opérable
M. Burgin (2009)
10.1097/CCO.0b013e3283297a50
Current World Literature
(2009)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
10.1634/theoncologist.2019-0574
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
K. Parikh (2019)
10.1016/j.ejca.2012.05.018
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
J. Blayney (2012)
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.2967/jnumed.108.053694
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
M. Benz (2008)
10.1200/JCO.2008.16.2545
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
S. Crabb (2009)
10.1016/J.EJCDT.2013.04.005
Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis
F. Amany (2013)
10.1016/j.cllc.2013.04.013
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
S. Ting (2013)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.2214/AJR.05.0076
Variability in mesothelioma tumor response classification.
S. Armato (2006)
10.1016/B978-1-4557-3383-5.00082-8
82 – Pleural Tumors
V. Broaddus (2016)
10.7314/APJCP.2012.13.7.3213
Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer.
S. Khokher (2012)
Tumor Response Assessment using CT and MRI: Current Clinical Practice
Frank H. Miller (2011)
10.2214/AJR.12.9862
A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers.
P. Rezai (2013)
10.1097/JTO.0b013e318260deaa
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma
D. Christoph (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar